Stem Cell Clinic

Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican …

By Stem Cell Treatment

Miami (PRWEB) October 07, 2013

The Global Stem Cells Group, Inc. has announced the launch of Plasma Plus medical services company in the Dominican Republic. Plasma Plus provides certified medical professionals, top of the line equipment, FDA approved protocols for hospitals, clinics and physicians, and protocol-specific equipment and consumables for application of platelet rich plasma therapy (PRP.)

Plasma Plus also assigns a qualified, certified health care professional to perform the PRP extraction and preparation procedures. Clients need only apply the therapy where needed to achieve the rejuvenating, regenerating and revitalizing results of PRP therapy, eliminating excess overhead costs, need for equipment purchases and preoccupation with maintaining protocol standards.

The benefits of PRP treatments extend through a wide and diverse group of medical fields, from cosmetic surgery to dentistry; Plasma Plus is committed to making PRP an available and cost-effective treatment option for medical professionals.

The companys product line includes:

The Plasma Plus equipment line includes:

For more information on Plasma Plus medical services, products and equipment, visit the Plasma Plus website, email info(at)www(dot)plasmaplusonline(dot)com(dot)do or call 849.943.2988.

About Plasma Plus:

Plasma Plus is an innovative, turn-key medical service company providing certified professionals, state-of-the-art equipment, and FDA approved protocols and kits for application of platelet rich plasma therapy (PRP). Plasma Plus technicians are trained and certified by a qualified team of medical professionals that includes physicians and nurses. Staffed by physicians, medical consultants and leading scientific researchers in the field to provide patients with the leading platelet rich plasma therapy.

PRP treatments utilize the bodys own resources to stimulate growth and regeneration with an overabundance of growth factors derived from platelets.

See original here:
Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican ...

BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium

By Stem Cell Treatment

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Adrian Harel, Director R&D, will present at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held October 14 & 15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

The following are specific details regarding BrainStorms presentation at the conference:

Event: Regen Med Partnering Forum 2013 Stem Cell Meeting on the Mesa Date: Monday, October 14, 2013 Time: 10:45 am Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARMs website shortly after the event.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement

Visit link:
BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium

Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India – Video

By Uncategorized


Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 days after Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy As reported by th...

By: Neurogen Brain and Spine Institute

Read the original here:
Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India - Video

Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India – Video

By Uncategorized


Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India
Improvement seen after Stem Cell Therapy Treatment for Spinal Cord Injury c6-c7 by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Standing toleran...

By: Neurogen Brain and Spine Institute

Read more from the original source:
Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India - Video

Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India – Video

By Uncategorized


Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 days after Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therap...

By: Neurogen Brain and Spine Institute

Original post:
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India - Video

Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India – Video

By Uncategorized


Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 days after Stem Cell Therapy Treatment for Cerebral Palsy (Spastic Quadriplegia) by Dr Alok Sharma, Mumbai, India. After Stem Cell...

By: Neurogen Brain and Spine Institute

Link:
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India - Video

Researchers unveil method for creating 're-specified' stem cells for disease modeling

By Stem Cell Treatment

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 19 hours ago

In a paper in Cell Stem Cell, a team led by researchers in the Boston Children's Hospital's Stem Cell Transplantation Program reports a new approach for turning induced pluripotent stem cells (iPSCs) into hematopoietic stem and progenitor cells for in vivo disease modeling.

With this strategywhich they call re-specificationthe team, including Sergei Doulatov, PhD, and George Daley, MD, PhD, of Boston Children's, may have overcome technical barriers to generating blood disease-specific animal models from the thousands of iPSC cell lines now sitting in laboratory freezers around the world.

The main advantage of the technique lies in the raw material. The research team started with iPSCs that had already been directed to grow into myeloid progenitors, which are more closely related to the desired blood progenitors than skin or other fully differentiated cell types commonly used in stem cell experiments.

The researchers then used a select set of transcription factors to turn back the molecular clock just a little on these committed myeloid cells, turning them into blood progenitors that readily engrafted and differentiated when transplanted into mice.

The re-specification technique could help generate the large number of engraftable cells needed to create animal models from iPSCs generated from human patients suffering a range of blood disorders, such as anemias, thalassemia or sickle cell disease.

Explore further: Scientists identify key regulator controlling formation of blood-forming stem cells

Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in ...

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published ...

Massachusetts General Hospital (MGH) researchers have used vascular precursor cells derived from human induced pluripotent stem cells (iPSCs) to generate, in an animal model, functional blood vessels that lasted as long as ...

Read the original post:
Researchers unveil method for creating 're-specified' stem cells for disease modeling

Leading experts offer advice on generating human induced pluripotent stem cell banks

By Stem Cell Treatment

Public release date: 3-Oct-2013 [ | E-mail | Share ]

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

The ability to make induced pluripotent stem cells (iPSCs) from mature cells in the body holds great potential for improved drug screening, disease modeling, and medical treatments for numerous conditions. Establishing well-characterized panels of iPSC lines that reflect the diversity of the human population and include samples from patients with a wide range of diseases will be key to tapping into the potential of iPSCs. In the October 3 issue of the Cell Press journal Cell Stem Cell, leading experts in the field publish several opinion pieces on emerging issues related to generating such iPSC banks, and they provide practical recommendations and creative solutions to address challenges associated with such large-scale efforts.

Dr. Glyn Stacey of the National Institute for Biological Standards and Control, located in the United Kingdom, and his colleagues recommend approaches for utilizing the knowledge of existing, well-established human embryonic stem cell banks and their experience in standardization to promote quality control in iPSC resource centers. "Not all laboratories will have the same level of expertise in cell culture or familiarity with vital quality control procedures. These will be essential to avoid the circulation of iPSC lines that have become contaminated or switched with other cell lines," says Dr. Stacey. "Such events can lead to fundamental flaws in the published literature and a waste of precious research resources."

In another Forum, Dr. Mahendra Rao, who is the director of the intramural Center for Regenerative Medicine at the National Institutes of Health, reiterates that making iPSC lines and developing the requisite controls and tests is time consuming, expensive, and generally beyond the expertise of any single laboratory. "Fulfilling the expectations for iPSCs and their use will only be possible if we develop a new cost-effective way to share and distribute cell lines. Crowd sourcing is one solution," he says. For the model to be successful, it must be self-sustaining. "Technology holders must buy in to the idea that it will ultimately benefit them as well as the users. It would also be important to ensure that expertise existed in the various repositories to store, characterize, test, and track the cells and their derivatives and that the repositories could do so at costs that were reasonable for the end user," writes Dr. Rao.

Finally, Dr. Ian Wilmut and his colleagues present a piece that addresses important considerations for immune matching between iPSC donors and recipients. They note that while it is possible that iPSC lines could be derived on an individual basis -- so that an individual patient would receive his or her own cells as a treatment -- it seems unlikely that this method would be used as a source for large numbers of patients in the near future due to time and cost restraints. A more practical solution is to build a bank of stem cell lines from a small pool of individuals that match a majority of the patient population and could be safely transplanted without immune rejection. "Calculations suggest that cells from approximately 150 selected people would provide a useful immunological match for the majority of people," explains Dr. Wilmut. "We propose that an international network of stem cell banks working with common procedures and standards should be established now in order to provide the broadest range of immunological types. This would be a critical step in ensuring widespread availability of high quality cell therapies in the future."

###

Cell Stem Cell, Turner et al.: "Towards The Development of a Global Induced Pluripotent Stem Cell Library."

Cell Stem Cell, Rao et al.: "iPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening."

Cell Stem Cell, Stacey et al.: "Banking Human Induced Pluripotent Stem Cells: Lessons Learned from Embryonic Stem Cells?"

Originally posted here:
Leading experts offer advice on generating human induced pluripotent stem cell banks

Okyanos Heart Institute Offers Educational Seminar About Cardiac Stem Cell Therapy In Lucaya, Grand Bahama

By Uncategorized

Freeport, The Bahamas (PRWEB) October 03, 2013

Okyanos Heart Institute, whose mission is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, has announced that they will be hosting a free educational seminar for the business community and all other interested individuals on Tuesday, October 22nd from 5:30 6:30 pm in the Coral Reef Room of the Pelican Bay Hotel in Lucaya, Grand Bahama Island. Registration is requested to attend as seating is limited.

Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and chief medical officer and interventional cardiologist for Okyanos Heart Institute will provide an overview of stem cell therapy for heart disease, the source of stem cells, how it is intended to work, and the protocol that will be used by the cath lab for patients once the facility is open in February, 2014. Erika Mangrum, SVP of Communications for the company, will provide an overview of what services will be needed by small businesses on the island, such as janitorial, hospital grade laundry, transportation, catering and more. A preliminary list of jobs that Okyanos Heart Institute will need to fill towards the end of the year will also be shared.

We welcome the local business community to learn about what we will be doing in treating patients with heart disease, said Walpole. Stem cell therapy is a growing field still with some confusion around where stem cells come from, what they do, and how they can potentially help someone with heart disease. We want to answer as many questions as we can.

President of The Grand Bahama Port Authority, Limited (GBPA) Ian Rolle, is pleased with how plans are progressing as the Institute prepares to open its doors locally in early 2014. Legislation has recently been enacted to support stem cell therapy, research and development in The Bahamas. This is of monumental proportions as Grand Bahama Island is now poised to become a leading centre for medical advancement, Rolle said. We heartily welcome the Okyanos Heart Institute and support their efforts towards public education. Additionally, the employment of skilled professionals and outsourcing of ancillary services, mean permanent engagement and greater business opportunities for many of our citizenry.

Okyanos Heart Institute will have a number of service needs from the local business community, said Mangrum. We hope to meet potential suppliers and servicers and share what our needs will be from service providers, and share employment needs once we are close to opening in February. We could not be more enthused about bringing patients to the beautiful island of Grand Bahama in the hopes of improving the quality of their lives by restoring flow to their hearts.

Registration for the seminar is requested as seating is limited. Call 242-688-2667 or email freeseminar(at)okyanos(dot)com by Oct 18.

ABOUT OKYANOS HEART INSTITUTE: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (Oceanos) symbolizes flow. For more information, go to http://www.okyanos.com.

Read more from the original source:
Okyanos Heart Institute Offers Educational Seminar About Cardiac Stem Cell Therapy In Lucaya, Grand Bahama

UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

By Stem Cell Treatment

Top ranked UFC bantamweight challenger Cat Zingano has been out of action for several months due to an injury to her right knee. That injury is on the mend, but it has led to issues with her left knee, for which Zingano will have a procedure on Thursday.

I am about three and a half months out (from the original injury), Zingano said on UFC Tonight. I went to my doctor on Monday. He said that Im right on track, so I should be coming back in another four months, something like March or April.

That is, of course, as long as the issues with her left knee can be rectified within that same time frame, which her doctor believes is the case.

Dr. Ronald S. Kvitne of the Kerlan-Jobe Orthopedic Clinic in Los Angeles on Monday told Zingano that if there was a tear in her left meniscus, as expected, that if they act quickly, it shouldnt extend the rehab time of her original injury.

Dr. Kvitne was initially thinking a surgery would be necessary, but Zingano on Wednesday indicated that Thursdays procedure would instead involve a stem cell treatment.

My left knee, because I think for the compensation for taking care of my right knee, has been taking a little bit more wear and tear than it was used to, said Zingano.

So Im going to have a procedure done with stem cells (on Thursday) that is going to be in place of having clean-up surgery instead.

If Zinganos rehabilitation remains on schedule, she would be able to return to the Octagon and fight sometime around April of 2014.

We think three months from now shed be back in the ring training, sparring, said Kvitne. So fighting in about four to six months from now.

Zingano also told UFC Tonight that she should expect to fight the winner of the Dec. 28 rematch between current UFC bantamweight champion Ronda Rousey and challenger Miesha Tate upon her return.

View original post here:
UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

→←